Vertex Pharmaceuticals (VRTX)
523.93
-11.24 (-2.10%)
NASDAQ · Last Trade: Oct 25th, 3:06 PM EDT
News & Press Releases
Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter Morefool.com
The company's gene-editing-focused platform looks promising.
Via The Motley Fool · October 24, 2026
Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change.fool.com
Vertex is expanding beyond its cystic fibrosis franchise.
Via The Motley Fool · October 24, 2026
Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase IIImarketbeat.com
Vertex Pharmaceuticals (NASDAQ:VRTX) outlined updates across its kidney disease pipeline at the American Society of Nephrology Kidney Week 2026, highlighting data for povetacicept in IgA nephropathy and inaxaplin in APOL1-mediated kidney disease, or AMKD.
Chief Executive Officer and President Reshm
Via MarketBeat · October 23, 2026
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below.
By Vertex Pharmaceuticals Incorporated · Via Business Wire · October 23, 2026
S&P 500 Premarket Movers on Oct. 21: Tech Hardware and AI Suppliers Gain, Health Care Declineschartmill.com
Via Chartmill · October 21, 2026
AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?fool.com
AbbVie generates $17.8 billion in annual free cash flow but faces patent cliffs, while Vertex boasts a 33% net margin with concentrated cystic fibrosis exposure.
Via The Motley Fool · October 20, 2026
Vertex Appoints Daniel Brennan to its Board of Directors
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Daniel Brennan has been appointed to its Board of Directors as an independent director. Mr. Brennan has more than 35 years of experience in finance roles at leading healthcare companies, including more than 25 years at Boston Scientific Corporation, a medical device and healthcare technology company. Mr. Brennan retired last year from serving as Boston Scientific’s Executive Vice President, Chief Financial Officer, where he had responsibility for all global finance functions and corporate business development.
By Vertex Pharmaceuticals Incorporated · Via Business Wire · October 20, 2026
Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive Itfool.com
Buffett has warned about "gambling" in the market.
Via The Motley Fool · October 19, 2026
Where Will CRISPR Therapeutics Stock Be in 2030?fool.com
The company's expertise in gene editing could lead to more breakthroughs.
Via The Motley Fool · October 18, 2026
Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.fool.com
Billionaire investor Cathie Wood, through her ARK ETFs, made big buys of CRISPR Therapeutics on Friday, Oct. 9, and Monday, Oct. 12.
Via The Motley Fool · October 18, 2026
1 Nasdaq 100 Stock on Our Watchlist and 2 That Underwhelm
The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like ...
Via StockStory · October 16, 2026
Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disordersfool.com
Vertex Pharmaceuticals is showing that it isn't a one-trick pony.
Via The Motley Fool · October 15, 2026
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?fool.com
Vertex raised its full-year outlook in Q2 with a growing pipeline across multiple disease areas. Moderna’s mRNA flu vaccine just cleared a key FDA hurdle with an expanding oncology pipeline behind it.
Via The Motley Fool · October 13, 2026
2 High-Flying Stocks on Our Watchlist and 1 We Question
“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ...
Via StockStory · October 12, 2026
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC).
By Vertex Pharmaceuticals Incorporated · Via Business Wire · October 9, 2026
Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right.fool.com
Most of any gains (or lack thereof) from here will be driven by just three factors.
Via The Motley Fool · October 9, 2026
Vertex to Announce Third Quarter 2026 Financial Results November 2nd
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2026 financial results on Monday, November 2, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Third Quarter 2026 Earnings Call.”
By Vertex Pharmaceuticals Incorporated · Via Business Wire · October 7, 2026
2 Safe-and-Steady Stocks with Promising Prospects and 1 We Turn Down
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on hi...
Via StockStory · October 5, 2026
Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?fool.com
One offers a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice comes down to whether you prioritize income stability or growth potential.
Via The Motley Fool · October 4, 2026
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?fool.com
Vertex dominates cystic fibrosis with expanding disease coverage and a pipeline entering new therapeutic areas. Axsome is building a commercial drug portfolio quickly but is still working toward consistent profitability.
Via The Motley Fool · October 1, 2026
2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right.fool.com
This biotech player is firing on all cylinders.
Via The Motley Fool · September 29, 2026
2 Healthcare Stocks to Target This Week and 1 We Avoid
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry...
Via StockStory · September 28, 2026
2 Healthcare Stocks That Just Delivered Great News for Investorsfool.com
And there could be more positive developments ahead.
Via The Motley Fool · September 26, 2026
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?fool.com
One is burning cash while chasing gene-editing breakthroughs. The other generates billions from a single therapy. Their divergent paths reveal starkly different risk-reward profiles.
Via The Motley Fool · September 24, 2026
Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD) and modest proteinuria and in people with AMKD and type 2 diabetes.
By Vertex Pharmaceuticals Incorporated · Via Business Wire · September 22, 2026